CCI Approves Merger of Nine Entities with Sequent Scientific

The Competition Commission approved the merger of nine entities with the pharmaceutical company Sequent Scientific Ltd (SSL). "The suggested merger entails a sequence of linked actions executed for the integration of SRL, Viyash, Symed, Appcure, Vindhya Pharma, Vandana, Vindhya Organics, Geninn, and SV Labs with SSL as the final surviving entity," stated CCI (Competition Commission of India) in a statement.

SSL provides active pharmaceutical ingredients (APIs), completed dosage forms, and analytical services for the animal health industry. Sequent Research Ltd (SRL), a fully-owned subsidiary of SSL, operates as a contract research organization.

Viyash is a pharmaceutical firm that, through its subsidiaries, is mainly involved in the development, production, and distribution of APIs and intermediates for human healthcare in India. Symed Labs, Appcure Labs, Vindhya Pharma (India), and Vandana Life Sciences are fully owned subsidiaries of Viyash, whereas S V Labs is a completely owned step-down subsidiary of Viyash.

The merger will enhance efficiency and bolster SSL's standing in the animal and human healthcare sectors. In a separate announcement, CCI stated that it has approved the planned acquisition of AI Lenarco Midco by Majesty II Pte Ltd, as well as certain compulsory convertible debentures in Manjushree Technopack from AI Lenarco by Ashoka India Equity Investment Trust plc, Nuvama Private Investment Trust, and InCred Growth Partners Fund - I.